ETR:SRT - Sartorius Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sartorius AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add €216.00 -1.00 (-0.46 %) (As of 02/21/2020 04:00 PM ET) Add Compare Today's Range€215.00Now: €216.00▼€220.0050-Day Range€171.00MA: €196.15▼€217.0052-Week Range€120.00Now: €216.00▼€220.00Volume727 shsAverage VolumeN/AMarket Capitalization$7.39 billionP/E Ratio86.09Dividend Yield0.29%BetaN/A ProfileAnalyst RatingsAdvanced ChartHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors. Read More… Industry, Sector and Symbol Stock Exchange ETR Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolETR:SRT Previous Symbol CUSIPN/A CIKN/A Webhttp://www.sartorius.com/ Phone49 551 308 0Debt Debt-to-Equity Ratio98.68 Current Ratio1.41 Quick Ratio0.70Price-To-Earnings Trailing P/E Ratio86.09 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.77 billion Price / Sales4.18 Cash Flow€1.29 per share Price / Cash Flow167.07 Book Value€12.10 per share Price / Book17.86Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees8,125 Outstanding Shares34,212,200Market Cap$7.39 billion Next Earnings DateN/A OptionableOptionable Receive SRT News and Ratings via Email Sign-up to receive the latest news and ratings for SRT and its competitors with MarketBeat's FREE daily newsletter. SRT Rates by TradingView Sartorius (ETR:SRT) Frequently Asked Questions What is Sartorius' stock symbol? Sartorius trades on the ETR under the ticker symbol "SRT." Has Sartorius been receiving favorable news coverage? Media stories about SRT stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sartorius earned a coverage optimism score of -3.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Sartorius. Who are some of Sartorius' key competitors? Some companies that are related to Sartorius include Carl Zeiss Meditec (AFX), Integral Diagnostics (IDX), Volpara Health Tech (VHT), Akumin (AKU), Profound Medical (PRN), Senseonics (SENS), Exagen (XGN), Renalytix Ai (RENX), Palatin Technologies (PTN), Oncosil Medical (OSL), Yourgene Health (YGEN), MaxCyte (MXCT), Lexagene (LXG), BARD1 Life Sciences (BD1) and Oncimmune (ONC). What other stocks do shareholders of Sartorius own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sartorius investors own include Align Technology (ALGN), Natus Medical (BABY), Cerner (CERN), Concert Pharmaceuticals (CNCE), Cytokinetics (CYTK), Deciphera Pharmaceuticals (DCPH), Endologix (ELGX), Epizyme (EPZM), EXACT Sciences (EXAS) and Fate Therapeutics (FATE). Who are Sartorius' key executives? Sartorius' management team includes the folowing people: Dr. Joachim Kreuzburg, Chairman of Exec. Board & CEO (Age 54)Mr. Rainer Lehmann, CFO & Member of Exec. Board and Head of Fin., Information Technology & Bus. Process (Age 43)Ms. Petra Kirchhoff, Head of Corp. Communications & Investor Relations and Member of Supervisory Board (Age 50)Mr. Gerry Mackay, Head of Lab Products & Services Division & Member of Exec. Board (Age 56)Dr. René Fáber, Head of Bioprocess Solutions Division & Member of Exec. Board (Age 43) What is Sartorius' stock price today? One share of SRT stock can currently be purchased for approximately €216.00. How big of a company is Sartorius? Sartorius has a market capitalization of $7.39 billion and generates $1.77 billion in revenue each year. Sartorius employs 8,125 workers across the globe.View Additional Information About Sartorius. What is Sartorius' official website? The official website for Sartorius is http://www.sartorius.com/. How can I contact Sartorius? The company can be reached via phone at 49 551 308 0. MarketBeat Community Rating for Sartorius (ETR SRT)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 38 (Vote Outperform)Underperform Votes: 56 (Vote Underperform)Total Votes: 94MarketBeat's community ratings are surveys of what our community members think about Sartorius and other stocks. Vote "Outperform" if you believe SRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2020 by MarketBeat.com StaffFeatured Article: What is a resistance level?
